Special Issue "Current Status on Molecular Therapeutic Targets for Neurodegenerative Disorders"
A special issue of Molecules (ISSN 1420-3049).
Deadline for manuscript submissions: 31 December 2020.
Interests: Drug discovery; therapeutics development for cancer and neurodegenerative disorders; computational molecular modeling
Interests: Molecular motors; Kinesin; Mechanisms of neurodegenerative disease; Intracellular transport
Neurodegenerative disease is an ensemble of over 600 diseases that affect millions worldwide. These diseases are characterized by a progressive loss of neuronal function leading to ataxia and/or dementia, with more severe forms causing death. Although there is plentiful ongoing research attempting to uncover the pathologies that lead to these neurodegenerative diseases, there are currently no available therapeutics that can either cure the diseases or address their progressive nature. The most common forms of neurodegenerative diseases are Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS). While neurodegenerative disorders tend to vary in clinical presentation, there are many pathological overlaps in their underlying mechanisms, including protein accumulation/misfolding/aggregation (seen in AD, PD, HD, and ALS), mitochondrial disfunction and oxidative stress (forms of AD, PD, HD, ALS), DNA damage/repair (AD, PD, ALS, ataxia telangiectasia, oculomotor apraxia), and intracellular transport (hereditary spastic paraplegia). As the molecular mechanisms underlying these various neurodegenerative diseases become better understood, they represent prime targets for therapeutic design in treating and potentially curing these disorders. Authors are invited to submit manuscripts to this Molecules Special Issue, “Current Status on Molecular Therapeutic Targets for Neurodegenerative Disorders”, in which all aspects related to molecular mechanisms, prime targets for therapeutic development, identification of biomarkers for diagnosis, agents in clinical trials, and challenges with current agents in various phases of clinical trials for neurodegenerative disorders may be addressed.
Dr. Jayalakshmi Sridhar
Dr. Thomas Huckaba
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neurodegenerative disorders
- molecular targets
- protein aggregation
- DNA damage and repair
- mitochondrion disorders
- therapeutic targets
- molecular pathways
- antibody target
- disease-specific selective target